WO2008064849A1 - Crystalline forms of zoledronic acid - Google Patents
Crystalline forms of zoledronic acid Download PDFInfo
- Publication number
- WO2008064849A1 WO2008064849A1 PCT/EP2007/010255 EP2007010255W WO2008064849A1 WO 2008064849 A1 WO2008064849 A1 WO 2008064849A1 EP 2007010255 W EP2007010255 W EP 2007010255W WO 2008064849 A1 WO2008064849 A1 WO 2008064849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- zoledronic acid
- crystalline form
- solid
- acid
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to new crystalline forms of low water soluble salts of zoledronic acid, the process for preparation of these crystalline forms, compositions containing these crystalline forms, and the use of these crystalline forms in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
- the invention relates to the crystalline monohydrate of the free acid of zoledronic acid, the process for preparation of the crystalline monohydrate of the free acid of zoledronic acid, compositions containing the crystalline monohydrate of the free acid of zoledronic acid, and the use of crystalline monohydrate of the free acid of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
- the invention relates to the crystalline trihydrate of the free acid of zoledronic acid, the process for preparation of the crystalline trihydrate of the free acid of zoledronic acid, compositions containing the crystalline trihydrate of the free acid of zoledronic acid, and the use of crystalline trihydrate of the free acid of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
- the invention relates to the crystalline anhydrous form of the free acid of zoledronic acid, the process for preparation of the crystalline anhydrous form of the free acid of zoledronic acid, compositions containing the crystalline anhydrous form of the free acid of zoledronic acid, and the use of crystalline anhydrous form of the free acid of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
- the invention also relates to the amorphous form of the free acid of zoledronic acid, the process for preparation of the amorphous form of the free acid of zoledronic acid, compositions containing the amorphous form of the free acid of zoledronic acid, and the use of the amorphous form of the free acid of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
- the drug zoledronic acid is used in the prevention of skeletal related events, (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone; treatment of tumor- induced hypercalcemia; Paget's disease, OP and prevention of recurrent hip fractures.
- skeletal related events pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia
- Paget's disease, OP prevention of recurrent hip fractures.
- the preparation of zoledronic acid is known in the art.
- different polymorphic forms of the same drug may have substantial differences in certain pharmaceutically important properties. Therefore, there is a continuing need for new solid forms of zoledronic acid and new methods of preparation.
- the invention provides a crystalline form of the calcium salt of zoledronic acid with a stoichiometry of one calcium and two zoledronic acid molecules, also known as "1:2 calcium salt of zoledronic acid".
- the crystalline form of the calcium salt of zoledronic acid with a stoichiometry of one calcium and two zoledronic acid molecules has an X-ray diffraction pattern with a peak at an angle of refraction 2 theta ( ⁇ ) of 7.8, 8.4, 9.3, 11.5, 14.3, 17.8, 19.4, 23.1 ⁇ 0.2 as depicted in Figure 1.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline form of the calcium salt of zoledronic acid with a stoichiometry of one calcium and two zoledronic acid molecules having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 7.8, 8.4, 9.3, 11.5, 14.3, 17.8, 19.4, 23.1 ⁇ 0.2 as depicted in Figure 1.
- Various embodiments and variants are provided.
- the invention provides a pharmaceutical composition that includes crystalline form of the calcium salt of zoledronic acid with a stoichiometry of one calcium and two zoledronic acid molecules and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention provides a crystalline form of the calcium salt of zoledronic acid with a stoichiometry of one calcium and one zoledronic acid molecule, also known as "1:1 calcium salt of zoledronic acid".
- the crystalline form of the calcium salt of zoledronic acid has an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 5.7, 6.5, 9.0, 10.6, 12.9, 17.4, 18.1 , 18.8, 19.7, 20.2 ⁇ 0.2 deg as depicted in Figure 2.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline form of the calcium salt of zoledronic acid with a stoichiometry of one calcium and one zoledronic acid molecule having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 5.7 and 6.5 ⁇ 0.2 as depicted in Figure 2.
- Various embodiments and variants are provided.
- the invention provides a pharmaceutical composition that includes crystalline form of the calcium salt of zoledronic acid with a stoichiometry of one calcium and one zoledronic acid molecule and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention provides a crystalline form I of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules.
- the crystalline form I of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules has an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 9.2, 9.5, 11.7, 15.5,18.1 , 20.5, 23.7, 24.3 ⁇ 0.2 deg as depicted in Figure 3.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline form I of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 9.2, 9.5, 11.7, 15.5,18.1 , 20.5, 23.7, 24.3 ⁇ 0.2 as depicted in Figure 3.
- Various embodiments and variants are provided.
- the invention provides a pharmaceutical composition that includes crystalline form I of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention provides a crystalline form Il of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules.
- the crystalline form Il of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules has an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 9.1, 13.0, 17.7, 18.0 ⁇ 0.2 as depicted in Figure 4.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline form Il of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 9.1 ⁇ 0.2 as depicted in Figure 4.
- Various embodiments and variants are provided.
- the invention provides a pharmaceutical composition that includes crystalline form Il of the zinc salt of zoledronic acid with a stoichiometry of one zinc and two zoledronic acid molecules and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention provides a crystalline form of the magnesium salt of zoledronic acid with a stoichiometry of one magnesium and two zoledronic acid molecules, also known as "1 :2 magnesium salt of zoledronic acid".
- the crystalline form of the magnesium salt of zoledronic acid with a stoichiometry of one magnesium and two zoledronic acid molecules has an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 4.5, 6.1, 7.7 ⁇ 0.2 as depicted in Figure 5.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline form of the magnesium salt of zoledronic acid with a stoichiometry of one magnesium and two zoledronic acid molecules having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 6.1, 7.7 ⁇ 0.2 as depicted in Figure 5.
- Various embodiments and variants are provided.
- the invention provides a pharmaceutical composition that includes crystalline form of the magnesium salt of zoledronic acid with a stoichiometry of one magnesium and two zoledronic acid molecules and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention provides a crystalline monohydrate of the free acid of zoledronic acid.
- the crystalline monohydrate of the free acid of zoledronic acid has an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 12.0, 12.8, 15.7, 18.8, 21.2, 21.7, 22.9 ⁇ 0.2 as depicted in Figure 6.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline monohydrate of the free acid of zoledronic acid, having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 12.8 ⁇ 0.2 as depicted in Figure 6.
- a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline monohydrate of the free acid of zoledronic acid, having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 12.8 ⁇ 0.2 as depicted in Figure 6.
- the invention provides a pharmaceutical composition that includes crystalline monohydrate of the free acid of zoledronic acid, and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention provides a crystalline trihydrate of the free acid of zoledronic acid.
- the crystalline trihydrate of the free acid of zoledronic acid has an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 9.2, 10.3, 10.7, 13.3, 16.3, 18.4, 21.5, 21.8, 22.8 ⁇ 0.2 as depicted in Figure 7.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline trihydrate of the free acid of zoledronic acid having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 9.2 and 10.3 ⁇ 0.2 as depicted in Figure 7.
- a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline trihydrate of the free acid of zoledronic acid having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 9.2 and 10.3 ⁇ 0.2 as depicted in Figure 7.
- Various embodiments and variants are provided.
- the invention provides a pharmaceutical composition that includes crystalline trihydrate of the free acid of zoledronic acid and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention provides a crystalline anhydrous form of the free acid of zoledronic acid.
- the crystalline anhydrous form of the free acid of zoledronic acid has an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 10.6, 12.9, 13.2, 16.2, 18.0, 21.2 ⁇ 0.2 as depicted in Figure 7.
- the invention provides a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline anhydrous form of the free acid of zoledronic acid having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 10.6 ⁇ 0.2 as depicted in Figure 8.
- a composition that contains zoledronic acid in a solid form, wherein at least 80% by weight of the solid zoledronic acid is its crystalline anhydrous form of the free acid of zoledronic acid having an X-ray diffraction pattern with a peak at an angle of refraction 2 ⁇ of 10.6 ⁇ 0.2 as depicted in Figure 8.
- Various embodiments and variants are provided.
- the invention provides a pharmaceutical composition that includes crystalline anhydrous form of the free acid of zoledronic acid and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is for oral administration.
- the invention also relates to the amorphous form of the free acid of zoledronic acid, the process for preparation of the amorphous form of the free acid of zoledronic acid, compositions containing the amorphous form of the free acid of zoledronic acid, and the use of the amorphous form of the free acid of zoledronic acid in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
- FIG. 1 shows the X-ray powder diffraction diagram of the crystalline form of the 1 :2 calcium salt of zoledronic acid.
- FIG. 2 shows the X-ray powder diffraction diagram of the crystalline form of the 1:1 calcium salt of zoledronic acid.
- FIG. 3 shows the X-ray powder diffraction diagram of the crystalline form I of the 1:2 zinc salt of zoledronic acid.
- FIG. 4 shows the X-ray powder diffraction diagram of crystalline form Il of the 1 :2 zinc salt of zoledronic acid.
- FIG. 5 shows the X-ray powder diffraction diagram of crystalline form of the 1 :2 magnesium salt of zoledronic acid.
- FIG. 6 shows the X-ray powder diffraction diagram of the crystalline form of the monohydrate of the free acid of zoledronic acid.
- FIG. 7 shows the X-ray powder diffraction diagram of the crystalline form of the trihydrate of the free acid of zoledronic acid.
- FIG. 8 shows the X-ray powder diffraction diagram of the crystalline form of the anhydrous form of the free acid of zoledronic acid.
- “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and includes that which is acceptable for veterinary use and/or human pharmaceutical use.
- Anti-solvent is a solvent which when added to an existing solution of a substance reduced the solubility of the substance.
- composition includes, but is not limited to, a powder, a solution, a suspension, a gel, an ointment, an emulsion and/or mixtures thereof.
- composition is intended to encompass a product containing the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- a “composition” may contain a single compound or a mixture of compounds.
- a “compound” is a chemical substance that includes molecules of the same chemical structure.
- composition is intended to encompass a product comprising the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
- pharmaceutical compositions of the present invention encompass any composition made by admixing the active ingredient, additional active ingredient(s) and pharmaceutically acceptable excipients.
- excipient means a component of a pharmaceutical product that is not the active ingredient, such as filler, diluent and carrier.
- excipients that are useful in preparing a pharmaceutical composition are preferably generally safe, non-toxic and neither biologically nor otherwise undesirable, and are acceptable for veterinary use, as well as human pharmaceutical use.
- a pharmaceutically acceptable excipient includes both one and more than one such excipient.
- “Therapeutically effective amount” means the amount of a compound that, when administered for treating or preventing a disease, is sufficient to effect such treatment or prevention for the disease.
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the patient to be treated.
- the terms “treating”, “contacting” and “reacting” are used interchangeably herein and refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or desired product. It should be appreciated that the reaction which produces the indicated and/or desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or desired product.
- essentially pure is understood in the context of the present invention to mean especially that at least 90%, preferably at least 95% by weight of the crystals of an acid addition salt of formula (I) are present in the crystal form according to the invention.
- Zoledronic acid is known as 1-hydroxy-2-(imidazol-1-yl)-ethane-1,1-diphosphonic acid and has the following chemical structure:
- U.S. Patent No. 4,939,130 claims zoledronic acid.
- the invention relates especially to a particular form preferably that which is referred to hereinafter as crystalline form I of the calcium salt of zoledronic acid, crystalline form Il of the zinc salt of zoledronic acid, crystalline form III of the magnesium salt of zoledronic acid, and crystalline form IV of the free acid monohydrate of zoledronic acid, described above.
- Different solid forms of the same drug may exhibit different properties, including characteristics that have functional implications with respect to their use as drug may have substantial differences in such pharmaceutically important properties as dissolution rates and bioavailability.
- different polymorphs may have different processing properties, such as hydroscopisity, flowability and the like, which could affect their suitability as active pharmaceuticals for commercial production.
- crystalline form of the 1 :2 calcium salt of zoledronic acid is approximately ⁇ 0.2 for each of the peak assignments.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the crystalline form of the 1 :2 calcium salt of zoledronic acid.
- the invention also provides a composition containing solid crystalline form of the 1 :2 calcium salt of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid crystalline form of the 1 :2 calcium salt of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the calcium salt of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the crystalline form of the 1:2 calcium salt of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the crystalline form of the 1 :2 calcium salt of zoledronic acid with respect to total weight of the solid in the composition.
- X-ray powder diffraction patterns was measured on a STOE STAPI P powder diffraction system with CuK alpha radiation source.
- the X-ray diffraction pattern depicted in FIG. 2 is summarized in Table 2.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the crystalline form of the 1:1 calcium salt of zoledronic acid.
- the invention also provides a composition containing solid crystalline form of the 1 :1 calcium salt of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid crystalline form of the 1:1 calcium salt of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the calcium salt of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the crystalline form of the 1 : 1 calcium salt of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the crystalline form of the 1:1 calcium salt of zoledronic acid with respect to total weight of the solid in the composition.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the crystalline form I of the 1 :2 zinc salt of zoledronic acid.
- the invention also provides a composition containing solid crystalline form I of the 1 :2 zinc salt of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid crystalline form I of the 1 :2 zinc salt of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the zinc salt of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the crystalline form I of the 1 :2 zinc salt of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the crystalline form I of the 1 :2 zinc salt of zoledronic acid with respect to total weight of the solid in the composition.
- X-ray powder diffraction patterns was measured on a STOE STAPI P powder diffraction system with CuK alpha radiation source.
- the X-ray diffraction pattern depicted in FIG. 4 is summarized in Table 4.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the crystalline form Il of the 1 :2 zinc salt of zoledronic acid.
- the invention also provides a composition containing solid crystalline form Il of the 1 :2 zinc salt of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid crystalline form Il of the 1 :2 zinc salt of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the zinc salt of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the crystalline form Il of the 1 :2 zinc salt of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the crystalline form Il of the 1 :2 zinc salt of zoledronic acid with respect to total weight of the solid in the composition.
- X-ray powder diffraction patterns was measured on a STOE STAPI P powder diffraction system with CuK alpha radiation source.
- the X-ray diffraction pattern depicted in FIG. 5 is summarized in Table 5.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the crystalline form of the 1 :2 magnesium salt of zoledronic acid.
- the invention also provides a composition containing solid crystalline form of the 1 :2 magnesium salt of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid crystalline form of the 1 :2 magnesium salt of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the magnesium salt of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the crystalline form of the 1 :2 magnesium salt of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the crystalline form of the 1 :2 magnesium salt of zoledronic acid with respect to total weight of the solid in the composition.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the crystalline monohydrate of the free acid of zoledronic acid.
- the invention also provides a composition containing solid crystalline monohydrate of the free acid of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid crystalline monohydrate of the free acid of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the crystalline monohydrate of the free acid of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the crystalline form Vl which is the crystalline monohydrate of the free acid of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the crystalline monohydrate of the free acid of zoledronic acid with respect to total weight of the solid in the composition.
- X-ray powder diffraction patterns was measured on a Scintag INC X1 with CuK alpha radiation source. The X-ray diffraction pattern depicted in FIG. 7 is summarized in Table 7.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the crystalline trihydrate of the free acid of zoledronic acid.
- the invention also provides a composition containing solid crystalline trihydrate of the free acid of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid crystalline trihydrate of the free acid of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the crystalline trihydrate of the free acid of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the crystalline trihydrate of the free acid of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the crystalline trihydrate of the free acid of zoledronic acid with respect to total weight of the solid in the composition.
- anhydrous form of the free acid of zoledronic acid is approximately ⁇ 0.2 for each of the peak assignments.
- One or more of physical properties and/or spectroscopic properties can be the basis for characterizing the crystal or polymorphic forms of the anhydrous form of the free acid of zoledronic acid.
- the invention also provides a composition containing solid anhydrous form of the free acid of zoledronic acid, which is at least 80%, by total weight of the composition.
- the preferred form of this composition is solid anhydrous form of the free acid of zoledronic acid powder suitable for use as active ingredient in formulating pharmaceutical products.
- the remainder of the composition i.e., 20% or less of the total weight of the anhydrous form of the free acid of zoledronic acid may be, e.g., other crystalline forms of low water soluble salts of zoledronic acid.
- the composition contains at least 90% of the anhydrous form of the free acid of zoledronic acid with respect to the total weight of the composition.
- the composition contains at least 95% of the anhydrous form of the free acid of zoledronic acid with respect to total weight of the solid in the composition.
- the invention also provides a process for making the crystalline form of the 1:2 calcium salt of zoledronic acid, the process including:
- the invention also provides a process for making the crystalline form of the 1 :1 calcium salt of zoledronic acid, the process including:
- the invention also provides for a process for making the crystalline form I of the 1 :2 zinc salt of zoledronic acid, the process including:
- the invention also provides for a process for making the crystalline form Il of the 1:2 zinc salt of zoledronic acid, the process including:
- the invention also provides for a process for making the crystalline form of the 1 :2 magnesium salt of zoledronic acid, the process including:
- the invention also provides for a process for making the crystalline form of the monohydrate of the free acid of zoledronic acid, the process including:
- the invention also provides for a process for making the crystalline form of the trihydrate of the free acid of zoledronic acid, the process including:
- the invention also provides for a process for making the crystalline form of the anhydrous form of the free acid of zoledronic acid, the process including:
- the pharmaceutical composition include one or more pharmaceutically acceptable carriers, also known as excipients, which ordinarily lack pharmaceutical activity, but have various useful properties which may, e.g., enhance the stability, sterility, bioavailability and ease of formulation of a pharmaceutical composition.
- These carriers are pharmaceutically acceptable, meaning that they are not harmful to humans or animals when taken appropriately and are compatible with other ingredients in a given formulation.
- the carriers may be solid, semi-solid or liquid, and may be formulated with the compound in bulk, but ultimately in the form of a unit-dose formulation, i.e., a physically discrete until containing a specific amount of active ingredient, such as a tablet or capsule.
- the pharmaceutical compositions may include, in addition to a compound of this invention, one or more active pharmaceutical compounds.
- the pharmaceutical compositions may be in the form of suspensions, solutions, elixirs, aerosols or solid dosage forms.
- the pharmaceutical compositions are contemplated in various formulations suitable for various modes of administration including, but not limited to, inhalation, oral, rectal, parenteral (including subcutaneous, intradermal, intramuscular and intravenous), implantable and transdermal administration.
- the most suitable route of administration in an given case depends on the duration of the subject's condition, the length of treatment desired, the nature and severity of the condition being treated, and the particular formulation that is being used.
- the formulations may be in bulk or in unit dosage form, and may be prepared by methods well-known in the art for a given formulation.
- a pharmaceutical composition will generally contain about 0.1% by weight to about 99% by weight of the active ingredient, preferably about 1% by weight to 50% by weight for oral administration and about 0.2% by weight to about 20% by weight for parenteral administration.
- Formulations suitable for oral administration include capsules (hard and soft), cachets, lozenges, syrups, suppositories and tablets, each containing a predetermined amount of the active compound; as a powder or granules, as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
- Such formulations may be prepared by any suitable method of pharmacy that includes the step of bringing into association the active compound and a suitable carrier or carriers.
- the amount of active ingredient per unit dosage of solid formulations may be as described in prior art for preparations of zoledronic acid.
- the invention also provides methods of treatment using the compounds and the pharmaceutical compositions of this invention.
- subject is meant a human or an animal, preferably human.
- Animals contemplated by this invention include any animal safely treatable by compounds of this invention.
- the present invention relates especially to crystalline form of the 1:2 calcium salt of zoledronic acid, the crystalline form of the 1 :1 calcium salt of zoledronic acid, the crystalline form I of the 1 :2 zinc salt of zoledronic acid, the crystalline form Il of the 1 :2 zinc salt of zoledronic acid, the crystalline form of the 1:2 magnesium salt of zoledronic acid, the crystalline form of the monohydrate of the free acid of zoledronic acid, the crystalline form of the trihydrate of the free acid of zoledronic acid, the crystalline form of the anhydrous form of the free acid of zoledronic acid disclosed herein for the treatment of one of the said diseases or in the preparation of a pharmacological agent for the treatment thereof.
- the invention relates also to a process for the treatment of warm-blooded animals suffering from said diseases, especially a tumor disease, wherein a quantity of the crystalline form of the 1:2 calcium salt of zoledronic acid, the crystalline form of the 1:1 calcium salt of zoledronic acid, the crystalline form I of the 1 :2 zinc salt of zoledronic acid, the crystalline form Il of the 1 :2 zinc salt of zoledronic acid, the crystalline form of the 1 :2 magnesium salt of zoledronic acid, the crystalline form of the monohydrate of the free acid of zoledronic acid, the crystalline form of the trihydrate of the free acid of zoledronic acid, the crystalline form of the anhydrous form of the free acid of zoledronic acid, which is effective against the disease concerned, especially a quantity with anti-proliferative and especially tumor-inhibiting efficacy, is administered to warm-blooded animals in need of such treatment.
- the invention relates moreover to the use of crystalline form of the 1 :2 calcium salt of zoledronic acid, the crystalline form of the 1 :1 calcium salt of zoledronic acid, the crystalline form I of the 1 :2 zinc salt of zoledronic acid, the crystalline form Il of the 1 :2 zinc salt of zoledronic acid, the crystalline form of the 1 :2 magnesium salt of zoledronic acid, the crystalline form of the monohydrate of the free acid of zoledronic acid, the crystalline form of the trihydrate of the free acid of zoledronic acid, the crystalline form of the anhydrous form of the free acid of zoledronic acid for the preparation of pharmaceutical compositions for use in treating the human or animal body, especially for the treatment of a variety of solid tumors and more specifically, e.g., breast cancer, colon cancer, ovarian cancer and leukemia.
- effective doses e.g., daily doses of about 1-2,500 mg, preferably 1-1 ,000 mg, especially 5-500 mg, are administered to warm-blooded animals of about 70 kg body weight.
- the invention relates also to pharmaceutical preparations which contain an effective amount, especially an effective amount for prevention or treatment of one of the said diseases, of crystalline form of the 1 :2 calcium salt of zoledronic acid, the crystalline form of the 1:1 calcium salt of zoledronic acid, the crystalline form I of the 1:2 zinc salt of zoledronic acid, the crystalline form Il of the 1 :2 zinc salt of zoledronic acid, the crystalline form of the 1 :2 magnesium salt of zoledronic acid, the crystalline form of the monohydrate of the free acid of zoledronic acid, the crystalline form of the trihydrate of the free acid of zoledronic acid, the crystalline form of the anhydrous form of the free acid of zoledronic acid or a combination of all crystalline forms together with pharmaceutically acceptable carriers which are suitable for topical; enteral, e.g., oral or rectal; or parenteral administration and may be inorganic or organic and solid or liquid.
- diluents e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycerin
- lubricants e.g., silica, talc, stearic acid or salts thereof, typically magnesium or calcium stearate; and/or PEG, are used for oral administration.
- Tablets may likewise contain binders, e.g., magnesium aluminum silicate, starches, typically corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; and, if so desired, disintegrants, e.g., starches, agar, alginic acid or a salt thereof, typically sodium alginate; and/or effervescent mixtures, or adsorbents, coloring agents, flavors and sweetening agents.
- binders e.g., magnesium aluminum silicate, starches, typically corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone
- disintegrants e.g., starches, agar, alginic acid or a salt thereof, typically sodium alginate
- effervescent mixtures e.g., effervescent mixtures, or adsorbents, coloring agents, flavors and sweetening agents
- Such solutions are preferably isotonic aqueous solutions or suspensions, these possibly being prepared before use, e.g., in the case of lyophilised preparations containing the active substance either alone or together with a carrier, e.g., mannitol.
- the pharmaceutical substances may be sterilised and/or may contain excipients, e.g., preservatives, stabilisers, wetting agents and/or emulsifiers; solubilizers; salts for the regulation of osmotic pressure; and/or buffers.
- the present pharmaceutical preparations which, if so desired, may contain further pharmacologically active substances, such as antibiotics, are prepared in a manner known perse, e.g., by means of conventional mixing, granulating, coating, dissolving or lyophilising processes, and contain from about 1-100%, especially from about 1% to about 20%, of the active substance or substances.
- Example 1 Process for Making the Crystalline Form of the 1 :2 Calcium Salt of Zoledronic acid
- Example 2 Process for Making the Crystalline Form of the 1 :1 Calcium Salt of Zoledronic Acid
- Example 3 Process for Making the Crystalline Form I of the 1 :2 Zinc Salt of Zoledronic Acid
- Example 5 Process for Making the Crystalline Form of the Monohydrate of the Free Acid of Zoledronic Acid
- Example 6 Process for Making the Crystalline Form of the Trihydrate of the Free Acid of Zoledronic Acid
- Example 7 Process for Making the Crystalline Form of the Anhydrous Form of the Free Acid of Zoledronic Acid
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0719567-2A BRPI0719567A2 (en) | 2006-11-27 | 2007-11-26 | ORGANIC COMPOUNDS |
US12/515,742 US20100056481A1 (en) | 2006-11-27 | 2007-11-26 | Crystalline forms of zoledronic acid |
EP07846821A EP2089404A1 (en) | 2006-11-27 | 2007-11-26 | Crystalline forms of zoledronic acid |
MX2009005413A MX2009005413A (en) | 2006-11-27 | 2007-11-26 | Crystalline forms of zoledronic acid. |
CA002670638A CA2670638A1 (en) | 2006-11-27 | 2007-11-26 | Organic compounds |
AU2007324833A AU2007324833A1 (en) | 2006-11-27 | 2007-11-26 | Crystalline forms of zoledronic acid |
JP2009537559A JP2010510970A (en) | 2006-11-27 | 2007-11-26 | Crystalline form of zoledronic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06124850.6 | 2006-11-27 | ||
EP06124850A EP1925621A1 (en) | 2006-11-27 | 2006-11-27 | Crystalline forms of zoledronic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008064849A1 true WO2008064849A1 (en) | 2008-06-05 |
Family
ID=37909616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/010255 WO2008064849A1 (en) | 2006-11-27 | 2007-11-26 | Crystalline forms of zoledronic acid |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100056481A1 (en) |
EP (2) | EP1925621A1 (en) |
JP (1) | JP2010510970A (en) |
KR (1) | KR20090083407A (en) |
CN (1) | CN101535323A (en) |
AR (1) | AR063923A1 (en) |
AU (1) | AU2007324833A1 (en) |
BR (1) | BRPI0719567A2 (en) |
CA (1) | CA2670638A1 (en) |
CL (1) | CL2007003389A1 (en) |
MX (1) | MX2009005413A (en) |
PE (1) | PE20081391A1 (en) |
RU (1) | RU2009123936A (en) |
TW (1) | TW200829598A (en) |
WO (1) | WO2008064849A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011014781A1 (en) | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
US8399023B2 (en) | 2009-07-31 | 2013-03-19 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
WO2017195031A1 (en) | 2016-05-13 | 2017-11-16 | Grunenthal Gmbh | Novel crystalline forms |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
US20180125869A1 (en) * | 2009-09-01 | 2018-05-10 | Duke University | Bisphosphonate compositions and methods for treating heart failure |
US10093691B2 (en) | 2009-07-31 | 2018-10-09 | Grunenthal Gmbh | Crystallization method and bioavailability |
EP3954386A4 (en) * | 2019-04-11 | 2022-07-06 | Xiamen Innovax Biotech Co., Ltd. | Preparation of zinc zoledronate micro-nanoparticle adjuvant and use thereof as vaccine adjuvant |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2407746C2 (en) * | 2008-09-29 | 2010-12-27 | ЗАО "Фарм-Синтез" | Radiopharmaceutical agent for diagnosing or treating (therapy) skeletal bone injuries and method of preparing said agent |
AU2011239935A1 (en) | 2010-04-16 | 2012-11-08 | Novartis Ag | Methods and compositions for improving implant osseointegration |
JP6492321B2 (en) * | 2015-03-23 | 2019-04-03 | 株式会社大阪合成有機化学研究所 | Process for producing [1-hydroxy-2- (imidazo [1,2-a] pyridin-3-yl) ethylidene] bisphosphonic acid monohydrate |
CN106749405B (en) * | 2016-12-29 | 2019-07-16 | 江苏省原子医学研究所 | A kind of imidazolyl heterocycle class double phosphinic acid compounds and preparation method thereof, application |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
CN110551152A (en) * | 2018-05-31 | 2019-12-10 | 四川科伦药物研究院有限公司 | Preparation method of zoledronic acid monohydrate and anhydrate crystal forms |
AU2020401286A1 (en) | 2019-12-13 | 2022-06-23 | Inspirna, Inc. | Metal salts and uses thereof |
CN112646193A (en) * | 2020-12-30 | 2021-04-13 | 华南理工大学 | Blocky calcium biphosphate complex and preparation method thereof |
CN112724174A (en) * | 2020-12-30 | 2021-04-30 | 华南理工大学 | Flaky calcium biphosphate complex and preparation method thereof |
CN112778365A (en) * | 2020-12-30 | 2021-05-11 | 华南理工大学 | Calcium zoledronate complex and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4244422A1 (en) * | 1992-12-29 | 1994-06-30 | Boehringer Mannheim Gmbh | New 1,1-bis:phosphonic acid magnesium and zinc salts |
US20040097468A1 (en) * | 2002-11-20 | 2004-05-20 | Wimalawansa Sunil J. | Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment |
US20050054616A1 (en) * | 2003-07-03 | 2005-03-10 | Judith Aronhime | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
US20060178439A1 (en) * | 2005-01-04 | 2006-08-10 | Mohakhud Pradeep K | Crystalline form of zoledronic acid |
WO2007016982A1 (en) * | 2005-07-28 | 2007-02-15 | Gador S.A. | A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it |
WO2007032808A1 (en) * | 2005-09-12 | 2007-03-22 | Dr. Reddy's Laboratories Ltd. | Crystalline trihydrate of zoledronic acid |
WO2007125521A2 (en) * | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
-
2006
- 2006-11-27 EP EP06124850A patent/EP1925621A1/en not_active Ceased
-
2007
- 2007-11-23 PE PE2007001630A patent/PE20081391A1/en not_active Application Discontinuation
- 2007-11-23 AR ARP070105215A patent/AR063923A1/en unknown
- 2007-11-26 BR BRPI0719567-2A patent/BRPI0719567A2/en not_active Application Discontinuation
- 2007-11-26 CL CL200703389A patent/CL2007003389A1/en unknown
- 2007-11-26 MX MX2009005413A patent/MX2009005413A/en not_active Application Discontinuation
- 2007-11-26 WO PCT/EP2007/010255 patent/WO2008064849A1/en active Application Filing
- 2007-11-26 US US12/515,742 patent/US20100056481A1/en not_active Abandoned
- 2007-11-26 CA CA002670638A patent/CA2670638A1/en not_active Abandoned
- 2007-11-26 TW TW096144824A patent/TW200829598A/en unknown
- 2007-11-26 AU AU2007324833A patent/AU2007324833A1/en not_active Abandoned
- 2007-11-26 RU RU2009123936/04A patent/RU2009123936A/en not_active Application Discontinuation
- 2007-11-26 CN CNA2007800419850A patent/CN101535323A/en active Pending
- 2007-11-26 JP JP2009537559A patent/JP2010510970A/en active Pending
- 2007-11-26 KR KR1020097010727A patent/KR20090083407A/en not_active Application Discontinuation
- 2007-11-26 EP EP07846821A patent/EP2089404A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4244422A1 (en) * | 1992-12-29 | 1994-06-30 | Boehringer Mannheim Gmbh | New 1,1-bis:phosphonic acid magnesium and zinc salts |
US20040097468A1 (en) * | 2002-11-20 | 2004-05-20 | Wimalawansa Sunil J. | Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment |
US20050054616A1 (en) * | 2003-07-03 | 2005-03-10 | Judith Aronhime | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
US20060178439A1 (en) * | 2005-01-04 | 2006-08-10 | Mohakhud Pradeep K | Crystalline form of zoledronic acid |
WO2007016982A1 (en) * | 2005-07-28 | 2007-02-15 | Gador S.A. | A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it |
WO2007032808A1 (en) * | 2005-09-12 | 2007-03-22 | Dr. Reddy's Laboratories Ltd. | Crystalline trihydrate of zoledronic acid |
WO2007125521A2 (en) * | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3158867A1 (en) | 2009-07-31 | 2017-04-26 | Thar Pharmaceuticals, Inc. | A method for increasing the aqueous solubility of a bisphosphonic acid or a bisphosphonate |
US8399023B2 (en) | 2009-07-31 | 2013-03-19 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US8933057B2 (en) | 2009-07-31 | 2015-01-13 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9334296B2 (en) | 2009-07-31 | 2016-05-10 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US10323052B2 (en) | 2009-07-31 | 2019-06-18 | Grunenthal Gmbh | Crystallization method and bioavailability |
WO2011014781A1 (en) | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
EP3295935A2 (en) | 2009-07-31 | 2018-03-21 | Grünenthal GmbH | Crystallization method and bioavailability |
US10093691B2 (en) | 2009-07-31 | 2018-10-09 | Grunenthal Gmbh | Crystallization method and bioavailability |
US20180125869A1 (en) * | 2009-09-01 | 2018-05-10 | Duke University | Bisphosphonate compositions and methods for treating heart failure |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
US10519176B2 (en) | 2010-11-24 | 2019-12-31 | Thar Pharma, Llc | Crystalline forms |
WO2017195031A1 (en) | 2016-05-13 | 2017-11-16 | Grunenthal Gmbh | Novel crystalline forms |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
EP3954386A4 (en) * | 2019-04-11 | 2022-07-06 | Xiamen Innovax Biotech Co., Ltd. | Preparation of zinc zoledronate micro-nanoparticle adjuvant and use thereof as vaccine adjuvant |
Also Published As
Publication number | Publication date |
---|---|
JP2010510970A (en) | 2010-04-08 |
EP2089404A1 (en) | 2009-08-19 |
BRPI0719567A2 (en) | 2013-12-10 |
US20100056481A1 (en) | 2010-03-04 |
MX2009005413A (en) | 2009-06-01 |
EP1925621A1 (en) | 2008-05-28 |
AR063923A1 (en) | 2009-02-25 |
PE20081391A1 (en) | 2008-11-14 |
RU2009123936A (en) | 2011-01-10 |
TW200829598A (en) | 2008-07-16 |
CA2670638A1 (en) | 2008-06-05 |
CN101535323A (en) | 2009-09-16 |
CL2007003389A1 (en) | 2008-06-27 |
AU2007324833A1 (en) | 2008-06-05 |
KR20090083407A (en) | 2009-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1925621A1 (en) | Crystalline forms of zoledronic acid | |
US8710216B2 (en) | Organic compounds | |
US8946272B2 (en) | Plymorphic forms of deferasirox (ICL670A) | |
WO2016155578A1 (en) | New crystal form of dapagliflozin and preparation method therefor | |
EP3160951B1 (en) | Crystalline forms of ferric maltol | |
EP1364959A1 (en) | Crystal of pyrimidine nucleoside derivative | |
ES2908072T3 (en) | Polymorph of sodium neridronate and method of preparing the same | |
CN113045554A (en) | Fexotinib crystal form and preparation method thereof | |
CS269719B1 (en) | Platinum cytostatic | |
US10526358B2 (en) | Crystalline forms | |
EP3517529B1 (en) | Salt of quinazoline derivative, preparation method therefor and application thereof | |
JP2018518515A (en) | Polymorphs of phenylaminopyrimidine compounds or salts thereof | |
EP2542546A1 (en) | Process for the preparation of a polymorph of strontium ranelate | |
CN116554110A (en) | Potassium fluorouracil monohydrate, crystal form thereof, preparation method and application | |
WO2007082946A1 (en) | Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents | |
BR112017008903B1 (en) | CRYSTALLINE FORMS OF FERRIC MALTOL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780041985.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07846821 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007846821 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007324833 Country of ref document: AU Ref document number: 2856/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12515742 Country of ref document: US Ref document number: MX/A/2009/005413 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009537559 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097010727 Country of ref document: KR Ref document number: 2670638 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2007324833 Country of ref document: AU Date of ref document: 20071126 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009123936 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0719567 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090527 |